Vyvanse Bed denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvanse bed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues a Not-FDA-Approved Denial for Vyvanse in BED

This denial category is unusual for Vyvanse used in binge eating disorder because the FDA granted an explicit BED indication for this drug. When BCBS issues a not-FDA-approved denial in this context, it typically reflects one of three administrative errors: (1) a coding mismatch — the claim was submitted under a diagnosis or NDC code the plan's system did not map to the BED indication; (2) an outdated plan policy that predates the FDA's approval; or (3) a formulary or utilization-management rule that was inadvertently classified as an approval-status denial. Any of these is correctable on appeal.

## Why This Denial Is Appealable

The FDA's approval of Vyvanse for moderate-to-severe binge eating disorder is a matter of public record, documented in the current prescribing label. An appeal that attaches the FDA label and identifies the specific BED indication directly refutes the stated denial reason. If the denial was triggered by a coding error, a corrected claim or a cover letter clarifying the diagnosis-to-drug mapping may resolve it quickly. If the plan's policy language is outdated, the external review process — which applies objective regulatory standards — provides a further corrective mechanism.

## Federal Appeal Framework

• Internal appeal — submit within the deadline on your denial notice (typically 180 days); include the FDA prescribing label as the primary exhibit.
• Corrected claim option — if the root cause is a coding issue, ask your prescriber's billing team to verify the diagnosis and drug codes before resubmitting; this can sometimes resolve the denial faster than the formal appeal track.
• External review (ACA §2719) — if the internal appeal is denied, fully-insured BCBS plans must allow independent external review; window is approximately four months from the final internal denial.
• ERISA §503 — self-funded employer plans must provide a full-and-fair review with a written explanation of any continued denial.
• Expedited track — available when a standard timeline would seriously jeopardize health.

## Documentation to Gather

1. FDA prescribing label (current) — the full label, with the BED indication section highlighted. 2. Diagnosis records — DSM-5-compliant documentation of moderate-to-severe BED. 3. Claim submission details — the original claim's diagnosis code(s) and drug/NDC code; verify these align with the BED indication. 4. Prescriber medical-necessity letter — confirming the indication and attesting that the use is consistent with the FDA-approved labeling. 5. BCBS denial letter — cite the exact language used to deny and rebut it point by point.

## Criteria-Mapping Structure

Because this denial type rests on a factual assertion (not FDA-approved), your appeal structure should be direct: state the denial's claim verbatim, then immediately present the FDA label language confirming approval for BED. Follow with diagnosis documentation confirming the patient has the labeled condition. If there is any ambiguity in how the claim was coded, address it explicitly so the reviewer cannot attribute the mismatch to anything other than an administrative error.